CJC-1295_Ipamorelin is a research peptide used in preclinical laboratory models involving metabolic, mitochondrial, immune, or regenerative pathways.

CJC-1295 (without DAC) + Ipamorelin (IPA) is a dual-peptide research combination developed for investigational and in vitro research use, formulated to study coordinated growth hormone–related signaling pathways. Both peptides are classified as growth hormone–releasing hormone (GHRH) and growth hormone secretagogue pathway modulators, respectively, but operate through distinct receptor mechanisms.

In preclinical and laboratory research models, CJC-1295 (without DAC) has been examined for its interaction with GHRH receptor signaling, while Ipamorelin has been studied for its selective activity at the ghrelin (GHS-R) receptor. As a combined formulation, this pairing is of interest in experimental studies exploring pulsatile growth hormone signaling dynamics, downstream IGF-1 pathway modulation, and anabolic signaling communication under controlled research conditions.

Mechanism of Interest

• Angiogenesis: Observed to influence vascular endothelial pathways.
• Tissue Repair: Supports modeling of gastric, tendon, and muscular healing.
• Cytoprotection: Evaluated for protective effects in oxidative environments.

Key Research Applications

• Tissue repair and regeneration research
• Inflammation pathway modeling
• Angiogenesis studies

Research Use Only

This product is supplied strictly for laboratory, research, and development use. Not for human consumption or therapeutic application.